C. Villanueva Bueno-rekin lankidetzan egindako argitalpenak (7)

2023

  1. Complementary and alternative medicine in cancer patients: characteristics of use and interactions with antineoplastic agents

    Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 2855-2882

  2. Medication guide for dose adjustment and management of cardiotoxicity and lipid metabolic adverse events of oral antineoplastic therapy

    Frontiers in Oncology, Vol. 13

2022

  1. A smartphone app to improve the safety of patients undergoing treatment with oral antineoplastic agents: 4 years of experience in a university hospital

    Frontiers in Public Health, Vol. 10

  2. Implantación de una metodología para evaluar patient‑reported outcomes en pacientes con cáncer de pulmón: Protocolo del estudio PeOpLe (Patient‑reported Outcomes in Lung cancer )

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 46, Núm. 4, pp. 265-269

  3. Medication guide for the perioperative management of oral antineoplastic agents in cancer patients

    Expert Opinion on Drug Safety, Vol. 21, Núm. 1, pp. 107-119

  4. Potential negative pharmacodynamic interaction of spironolactone and abiraterone in two prostate cancer patients

    Journal of Oncology Pharmacy Practice, Vol. 28, Núm. 5, pp. 1259-1263

  5. Smartphone-Based Ecological Momentary Assessment for the Measurement of the Performance Status and Health-Related Quality of Life in Cancer Patients Under Systemic Anticancer Therapies: Development and Acceptability of a Mobile App

    Frontiers in Oncology, Vol. 12